New immunotherapy approach holds promise for ovarian cancer
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
List view / Grid view
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
Combining AI with cutting-edge flow cytometry and massive sequencing technologies, researchers describe CAR T cell characteristics that determine their therapeutic capacity for the first time.
In their study, researchers duped antibodies with a decoy to prevent rejection of transplanted cells.
US researchers, using new machine learning techniques have developed a virtual molecular library of “words” that encode commands to kill cancer cells.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Researchers have developed a new method for comparing CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer.
A team of scientists have 3D bioprinted breast cancer tumours and treated them in a new study, offering greater understanding of the disease.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.